News

Podcast

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Expert weighs in on data from the AQUILA trial and Johnson & Johnson's approval request for daratumumab for smoldering multiple myeloma.

In this episode, we dive deep into the complexities around the treatment of smoldering multiple myeloma. Our guest, Ming-Hei Tai, a clinical oncology pharmacist, provides a comprehensive overview of the current landscape, including the controversies surrounding the AQUILA trial. Ming shares his concerns about the trial design, highlighting the need for trials that prioritize clinically relevant endpoints like overall survival and prevention of end-organ damage, rather than just asymptomatic progression. The discussion also explores the evolving definitions of myeloma and smoldering myeloma, as well as the potential future role of emerging immunotherapies.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Image credit: Dr_Microbe | stock.adobe.com